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Abstract
The juvenile form of neuronal ceroid Lipofuscinosis (JNCL) is the most common form within this group of rare
lysosomal storage disorders, causing pediatric neurodegeneration. The genetic disorder, which is caused by
recessive mutations affecting the CLN3 gene, features progressive vision loss, cognitive and motor decline and
other psychiatric conditions, seizure episodes, leading to premature death. Animal models have traditionally aid the
understanding of the disease mechanisms and pathology and are very relevant for biomarker research and
therapeutic testing. Nevertheless, there is a need for establishing reliable and predictive human cellular models to
study the disease. Since patient material, particularly from children, is scarce and difficult to obtain, we generated
an engineered a CLN3-mutant isogenic human induced pluripotent stem cell (hiPSC) line carrying the c.1054C→ T
pathologic variant, using state of the art CRISPR/Cas9 technology. To prove the suitability of the isogenic pair to
model JNCL, we screened for disease-specific phenotypes in non-neuronal two-dimensional cell culture models as
well as in cerebral brain organoids. Our data demonstrates that the sole introduction of the pathogenic variant
gives rise to classical hallmarks of JNCL in vitro. Additionally, we discovered an alteration of the splicing caused by
this particular mutation. Next, we derived cerebral organoids and used them as a neurodevelopmental model to
study the particular effects of the CLN3Q352X mutation during brain formation in the disease context. About half of
the mutation -carrying cerebral organoids completely failed to develop normally. The other half, which escaped this
severe defect were used for the analysis of more subtle alterations. In these escapers, whole-transcriptome analysis
demonstrated early disease signatures, affecting pathways related to development, corticogenesis and synapses.
Complementary metabolomics analysis confirmed decreased levels of cerebral tissue metabolites, some particularly
relevant for synapse formation and neurotransmission, such as gamma-amino butyric acid (GABA). Our data
suggests that a mutation in CLN3 severely affects brain development. Furthermore, before disease onset, disease
-associated neurodevelopmental changes, particular concerning synapse formation and function, occur.
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Introduction
Juvenile neuronal ceroid lipofuscinosis (JNCL), also
commonly referred to as Batten disease or CLN3 disease
(OMIM #204200) belongs to the neuronal ceroid lipo-
fuscinoses: a larger group of lysosomal storage disorders
which represent a major cause of neurodegeneration in
children and young adults [6, 81]. With an estimated in-
cidence range of 0.2–7 per 100,000 births worldwide,
and an increased prevalence in northern European pop-
ulations [38, 76], JNCL is considered a rare disease. Its
symptoms typically manifest between 4 and 8 years of
age with a rapid and progressive vision loss [59]. The
disease advances with cognitive [42] and motor decline
[43], accompanied by seizure episodes and behavioural
changes, and inevitable leads to premature death during
the second or the third decade of life, in the classical dis-
ease phenotype [71]. In addition to neurodegeneration,
neurodevelopment may also be affected. Although ani-
mal models have broadened our knowledge about dis-
ease mechanisms, protein localization, function and
interactions, the neurodevelopmental component to
JNCL is still poorly understood. Only a few studies were
able to show to some extent developmental abnormal-
ities in newborn mice [58] or zebra fish embryos and lar-
vae [78]. However, they might not recapitulate the
features of the human disease.
JNCL is caused by recessively inherited mutations
in the CLN3 gene [33]. Up to date, a total number of
67 different mutations occurring in the CLN3 gene
have been compiled by the NCL Mutation and Pa-
tient Database (http://www.ucl.ac.uk/ncl/CLN3muta-
tiontable.htm). Whereas most of the JNCL patients
(80–85%) are homozygous for a 1.02 kb deletion of
exons 7 and 8, compound heterozygous cases or
homozygous for the different single nucleotide vari-
ants are scarce and usually manifest in one or few
families [41]. The existence of CLN3 missense muta-
tions that cause other disorders emphasises the need
to study these variants closely [79]. Initial studies
using patient-specific human induced pluripotent stem
cells (hiPSCs) showing in vitro effects of CLN3 muta-
tions on the endocytic pathway and calcium homeo-
stasis and autophagy have been published [18, 49].
However, patient-derived hiPSCs have the drawback
that, aside from the disease-associated mutations, they
carry the genetic background of the affected individ-
uals, which can be extremely diverse between pa-
tients, making associating phenotypes directly to a
particular gene mutation a complicated task. To over-
come these limitations, we used state of the art
CRISPR/Cas9 genome editing technologies [4] and in-
troduced a disease-causing mutation into the CLN3
gene of healthy hiPSCs. The newly generated isogenic
pair represents an advantage compared to gene
corrected cell lines [83], as it allows to study the con-
tribution of a particular mutation to the disease
phenotype, without any concomitant effect of the pa-
tient’s genetic background.
In this study, we used cerebral organoids as model for
early brain development [45, 51] to investigate whether
CLN3 deficiency affects fundamental neurodevelopmen-
tal mechanisms, such as growth and differentiation. Our
results highlight transcriptional and metabolomic
changes in CLN3 mutant organoids, when compared to
controls, which indicate imbalances during brain devel-
opment. Here, we provide a proof of principle that our
cellular model recapitulates key disease features in dif-
ferent cell types in vitro and is thereby suitable for mod-
eling JNCL.
Results
Generation of a CLN3 mutant isogenic pair
To insert the c.1054C→ T pathologic variant on the
CLN3 gene, we designed a 21 bp sgRNA that targets
the exon 13 of the human CLN3 locus to produce a
Cas9- induced double-strand break. In order to
visualize and follow the genotypic outcome of the
editing, excluding random integration, we applied the
FACS assisted CRISPR-Cas9 genome editing (FACE)
pipeline [3, 35]. Briefly, to promote homologous re-
combination, we created two double-stranded DNA
donors containing a positive selection module with ei-
ther EGFP or dTOMATO and the puromycin resist-
ance gene, flanked by approximately 1 Kb homology
arms. The left homology arm contained, in both do-
nors, the c.1054C→ T single nucleotide change for a
homozygous outcome (Fig. 1a). In a first step, the
constructs were introduced into the genome of
healthy control hiPSCs. Puromycin-selected cells were
collected, and a double-positive population was se-
lected through several rounds of cell sorting, exclud-
ing the ones containing random integration events
(BFP positive). Despite the fact that biallelic targeting
occurred initially in a frequency of 0.6%, the entire
population could be enriched (Fig. 1b). In a second
step, the positive selection module was excised by ex-
ogenously expressing the excision-only variant of the
PiggyBac transposase [47]. Subsequently, the double-
negative population could be purified by cell sorting
(Fig. 1c). Precise introduction of the mutation in ho-
mozygosis was confirmed by Sanger sequencing. Add-
itionally, silent mutations in the PAM sequence,
introduced to shield the site from Cas9 after inser-
tion, were also present and in homozygosis, repre-
senting a successful editing procedure (Fig. 1d).
Pluripotency of the lines was evaluated by immuno-
staining for OCT4, SOX2, TRA1–81, TRA1–60 and
SSEA4 (Additional file 1: Figure S1b). Karyotype
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assessment revealed no major abnormalities in both
the edited polyclone and the parental control lines
(Additional file 1: Figure S1c). Potential off-target loci
for the utilized sgRNA (refer to CLN3-QtoO-B in
methods section) were predicted by the CRISPR/Cas9
target online predictor, CCTOP [73]. For the top
seven off-target sites, we designed a pair of primers
to amplify between 200 and 900 bp of the predicted
region. Sanger sequencing analysis revealed no detect-
able off-target modifications induced in the isogenic
pair by the genome editing process (Additional file 6:
Table S2).
The CLN3 p.Q352X mutation causes a novel splicing
variant
The c.1054C→T mutation is located at the last codon of
exon 13 from the CLN3 gene and it produces a premature
termination codon (PTC), responsible for generating a
truncated protein [55]. Brooks and colleagues reported a fre-
quency of 2.8% of PTC-inducing mutations for the CLN3
gene [12]. In addition, PTCs are shown to frequently induce
alternative splicing, often leading to skipping of the PTC-
containing exon [17]. To test this hypothesis in the here
generated isogenic line, reverse-transcription PCR (RT-PCR)
analysis using primers that amplified exons 11 to 15, re-
vealed two different cDNA amplicons in the CLN3 mutant
hiPSCs, one with the expected normal size (480 bp) and a
product of around 100 bp smaller in size (Fig. 1e). Sanger se-
quencing confirmed that the smaller product corresponded
to an exon-skipped variant, which lacked exon 13 (Fig. 1f).
To our knowledge, the potential affection of the splicing by
the p.Q352X mutation was not previously described. There-
fore, we further investigated this alternative splicing variant
in peripheral blood mononuclear cells (PBMCs) extracted
from a patient carrying the same mutation in homozygosity.





Fig. 1 Gene editing-mediated introduction of the c.1054C > T mutation in the CLN3 locus alters splicing. a Representation of biallelic donors
containing distinctive fluorescent positive selection modules (PSM) and the targeted genomic region. b FACS plots depicting the different
populations through the steps of the editing process. The upper panel represents the line after the integration of the PSM and the lower panel,
the enrichment of the line after several rounds of sorting for the double-positive population. Plots are accompanied in the right side by
microscope images for proper visualization of each step. Scale bars, 200 μm. c FACS plots depicting the different populations through the steps
of the editing process. The upper panel represents the line after the excision of the PSM and the lower panel, the purification of the line after
several rounds of sorting for the double-negative population. Plots are accompanied in the right side by microscope images for proper
visualization of each step. Scale bars, 200 μm. d Sanger sequencing chromatogram of the obtained polyclone highlighting the introduction of the
mutation and the silent PAM modifications. e Representative RT-PCR gel showing the different band amplification sizes in the CLN3Q352X mutant
hiPSCs and patient PBMCs, as compared to the controls. f Second band corresponds to an exon-skipping event of the mutated exon. Sanger
sequencing confirmed the junction between neighboring exons
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proportion of the two variants seems to differ, which might
be caused by cell type specific differences (Fig. 1e).
CLN3Q352X hiPSC-derived endothelial cells recapitulate
JNCL disease hallmarks
In juvenile neuronal ceroid lipofuscinosis the ultrastruc-
tural visualization of storage material, in a distinctive
pattern, called fingerprint profiles (FPPs) constitutes a
disease hallmark. Following the study from Pérez-Poyato
and colleagues, that used endothelial cells (ECs) to
characterize storage inclusions in CLN3 patients [62],
we derived endothelial cells (ECs) from the here gener-
ated hiPSC isogenic pair and investigated the potency of
the CLN3Q352X mutant line to recapitulate storage dis-
order pathology. Cell differentiation towards the endo-
thelial lineage was assessed by immunostaining of the
endothelial cell surface marker CD31, showing a similar
staining distribution in both cell lines (with a mean
fluorescence intensity of 0.76 ± 0.05 in the Control and
0.84 ± 0.04 in the CLN3Q352X ECs) (Fig. 2a). The differ-
ent cellular compartments and organelles were examined
by transmission electron microscopy (TEM) after 15
days of differentiation. We observed major autophagic
structures, constituted by a single limiting membrane
and cellular components at various stages of degrad-
ation, which represent autophagic vacuoles (AVs)
(Fig. 2b). Quantification of the percentage of AVs per
cell profile highlighted a significantly increased presence
of these structures in the CLN3Q352X mutant line
(15.57 ± 2.7% in the Control and 55.27 ± 12.9% in the
CLN3Q352X ECs). Although the AV area normalized to
total cell area was not significantly different, there was a
trend towards an increased size of the AVs in the case of
the mutant cells (0.64 ± 0.15% in the Control versus
5.38 ± 4.02% in the CLN3Q352X ECs) (Fig. 2c). Strikingly,
we were also able to find electron dense storage material
with fingerprint patterned morphology in the
CLN3Q352X mutant ECs, which looked very similar to
the storage material typically observed in JNCL patients
(Fig. 2d) [49, 54]. The observation of the classical storage
material by TEM prompted us to further examine the
ECs by immunostaining of the subunit c of the mito-
chondrial ATP synthase (SCMAS) and the lysosomal-
associated membrane protein 1 (LAMP1). We observed
a significantly higher amount of LAMP1 and SCMAS
positive structures in the CLN3Q352X mutant ECs, as
well as a significantly higher degree of co-localization
between the two structures, indicative of an increased
presence of SCMAS inside the lysosomes in the case of
the mutant ECs, which may be part of the aberrant stor-
age material (Fig. 2e, f). Alterations were not only re-
stricted to the lysosomal compartment. Golgi stacks
were often broadened up in the case of the CLN3Q352X
mutant cells (Fig. 2g). Consequently, we immunostained
to visualize the cis-Golgi marker GM130 (Fig. 2h). Image
analysis revealed a lower proportion of Golgi structures
in the CLN3Q352X mutant ECs but with a higher degree
of ramification, as seen by the increased amount of
pixels that form the Golgi skeleton and the average of
ramification points (or nodes) per Golgi structure
(Fig. 2i). Evaluation of other organelles revealed no ultra-
structural abnormalities in the endoplasmic reticulum
(ER) (Additional file 2: Figure S2a), the endosomal mem-
branes (early endosomes and late endosomes/lysosomes)
(Additional file 2: Figure S2b), or the mitochondria
(Additional file 2: Figure S2c) in the CLN3Q352X ECs.
However, immunostaining for the Ras-related protein
Rab-7a (RAB7) (Additional file 2: Figure S2d), a small
GTPase that plays a key role in regulating the transport
from early to late endosomal compartments [29],
highlighted a significantly decreased amount of RAB7
positive structures, which are also smaller in size on
average, in the CLN3Q352X ECs compared to the Control
cells (Additional file 1: Figure S2e). As RAB7 is a key
regulator of the transport into degradative compart-
ments [15], these results are a further indication for de-
fects in the maturation and/or trafficking of the endo-
lysosomal compartments in CLN3Q352X ECs.
Severe failure to develop in CLN3Q352X hiPSC-derived
cerebral organoids
Little is known about early brain development in the
context of JNCL. To evaluate whether there is an early
developmental component to CLN3 disease, we used
cerebral organoids as a state of the art human model to
study brain development and disease [1, 45, 51, 66]. In
this regard, we generated cerebral organoids from the
here generated hiPSC isogenic pair [44] and we cultured
them up to the stage where cortical markers are typically
expressed (55 days of differentiation) [69]. Initial screen-
ing involving size evaluation of individual organoids up
to the stage of neural induction (day 10) revealed no
major differences (Additional file 3: Figures S3a, b).
However, upon matrix embedding and initiation of the
differentiation (day 11), the average size of CLN3Q352X
organoids was slightly, but significantly reduced, in com-
parison to the isogenic control without the mutation
(Fig. 3a, b). Interestingly, about half of the CLN3Q352X
organoids completely failed to grow and develop further
until the end-point of the differentiation (Fig. 3c, d).
This severe phenotype was observed repeatedly across
several organoid generations. The other half of mutant
organoids, which escaped this severe defect were used
for the analysis of more subtle alterations. In these fully-
developed cerebral organoids, with and without mutant
CLN3, comparable expression of brain identity markers,
such as the forebrain marker FOXG1 were detected, ei-
ther via immunofluorescence or western blot. Neuronal
Gomez-Giro et al. Acta Neuropathologica Communications           (2019) 7:222 Page 4 of 19
Fig. 2 (See legend on next page.)
Gomez-Giro et al. Acta Neuropathologica Communications           (2019) 7:222 Page 5 of 19
marker MAP 2 was also present and neuronal identity
corresponding to several cortical layers, like SATB2 ex-
pression for later-born superficial-layer identity neurons,
and early-born deep-layer identity marked by the expres-
sion of CTIP2 and TBR1 were detectable at comparable
levels. Moreover, they also expressed neural stem cell
markers SOX2 and Nestin (Fig. 3e, f) [68]. However,
mRNA levels of FOXG1, SATB2 and TBR1 genes were
found significantly downregulated in the CLN3Q352X
mutant phenotype (Additional file 5: Figure S5a). Finally,
TEM analysis highlighted the presence of nerve fibers
with neurofilaments and synaptic vesicles in both geno-
types (Fig. 3g). Based on these results we conclude that
about half of the CLN3Q352X organoids were able to es-
cape severe development defects which prohibit their de-
velopment into cerebral organoids. We decided to further
analyse these escapers for more subtle defects that might
be caused by presence of the CLN3Q352X mutation.
CLN3 mutant cerebral organoids present lysosomal
alterations, storage pathology and astrocytosis
Ultrastructural analysis of CLN3Q352X mutant cerebral
organoids confirmed the presence of pathological storage
material, as seen by the increased presence of AVs (Fig. 4a)
of significantly greater area in the case of the CLN3Q352X
organoids (4.9 ± 0.75) compared to the Control organoids
(3.28 ± 0.86) (Fig. 4b). Strikingly, we were also able to find
intracytoplasmic and electron dense storage material with
fingerprint morphology in the CLN3Q352X organoids mu-
tant organoids [54], as well as structures resembling curvi-
linear bodies (CVB) [9] (Fig. 4c, d). Pathological
intracellular deposits in JNCL are typically autofluorescent
[70] and composed mainly of subunit c of the mitochon-
drial ATPase (SCMAS) [60]. However, autofluorescence
analysis in organoid sections with confocal laser excitation
at 568 nm [52] did not reveal any increase in the
CLN3Q352X mutant organoids (Additional file 3: Figures
S3c, d). SCMAS protein levels were also not significantly in-
creased (Additional file 3: Figures S3e, f). To determine
whether the storage material results in an impairment of
lysosomal functionality, we analyzed the protein levels of
TPP1/CLN2, a serine protease in the lysosome, which in-
teracts with CLN3 [77], and found a significant increase in
CLN3Q352X organoids (Fig. 4e, f). However, at the gene ex-
pression level, mRNA counts for the TPP1 gene were sig-
nificantly decreased in the CLN3Q352X mutant organoids
(Additional file 5: Figure S5b). Additionally, CLN3 has also
been implicated in the regulation of other proteases in the
lysosome, including Cathepsin D (CTSD/CLN10) [16, 26].
We detected a significantly decreased concentration of
CTSD in lysates from CLN3Q352X cerebral organoids
(Fig. 4g), suggesting that functional alterations at the lyso-
somal level are already present at this time-point in this de-
velopmental model. This is important because not only
these proteins are thought to interact with the CLN3 gene,
but mutations in TPP1, as well as CTSD cause late-infantile
and congenital NCL, respectively [6]. Additionally, we
found increased astrocytosis, indicated by the significant in-
crease of GFAP+ cells, in CLN3Q352X mutant organoids
(Fig. 4h, i), which has been often reported in CLN3 deficient
mice brains [8, 61, 63]. Differences in MAP 2-positive neur-
onal areas were not significant, however, a trend towards a
decreased neuronal areas that may be due to an increased
astrocytosis could be observed (Fig. 4i). Furthermore, we
were not able to detect increased percentages of apoptotic
TUNEL+ DAPI+ cells in CLN3Q352X organoids (Additional
file 3: Figures S3 g and h), and programmed necrosis (or
necroptosis) marker levels, such as kinases receptor-
interacting proteins 1 and 3 (RIP1 and RIP3) [7], were not
significantly different from the ones in the Control organoids
(See figure on previous page.)
Fig. 2 The CLN3 c.1054C > T introduction generated classical JNCL phenotypes in vitro. a Protocol for endothelial cell (EC) derivation from hiPSCs
and representative immunofluorescence pictures of CD31 positive endothelial cells for characterization. Scale bar, 200 μm. Quantification of CD31
positive cells performed in Control and CLN3Q352X ECs. Mean fluorescence intensity of the CD31 channel normalized to the nuclear (Hoechst
positive) signal was calculated for 12 random fields per condition using ImageJ (NIH) (Welch’s test; ns, not significant). Data is shown as mean ±
SEM. b Representative TEM pictures highlighting increased presence of autophagic vacuoles (AVs, yellow dashed line) in the CLN3Q352X ECs. Other
organelles (n, nuclei; g, Golgi; l, lysosome; m, mitochondria). Scale bars, 1 μm. b Quantification of the percentage of AVs evaluated as the number
of events in 56 Control and 52 CLN3Q352X random cell profiles. Area of the AVs was calculated on ImageJ (NIH) by manually delineating the
perimeter as regions of interest (ROI). AV areas were normalized to the total area of the cell containing them. All measurements were corrected
for the magnification of the pictures if needed. Comparison between genotypes was performed by a Mann-Whitney test (*p < 0.05; ns; not
significant). Data is shown as mean ± SEM. d Representative TEM pictures of fingerprint inclusions (FPPs) seen in CLN3Q352X ECs (Gly, glycogen
deposits). Scale bar, 500 nm. Zoomed in picture (yellow dashed square) for better visualization of membrane stacks. Scale bar, 200 nm. e High-
content imaging of SCMAS (green), LAMP1 (red) structures, and co-localization events (yellow) in Control and CLN3Q352X ECs. Scale bar, 200 μm. f
SCMAS, LAMP1 and colocalization counts normalized to the nuclear (Hoechst positive) area of each field. Differences were evaluated using Mann-
Whitney test (*p < 0.05, ****p < 0.0001). Data is represented as mean ± SEM of three technical replicates. g Representative TEM images of structural
differences in the Golgi compartment in the Control (stacked) and the CLN3Q352X (dilated) ECs (g, Golgi; m, mitochondria; gly, glycogen). Scale
bars, 500 nm. h High-content imaging of Golgi (GM130 positive) structures (red). Scale bar, 200 μm. i Quantification of GM130 counts, normalized
to the nuclear (Hoechst positive) area of each field. GM130 positive structures present an increased ramification in terms of skeleton pixels and
average nodes per Golgi structure. Comparison performed with Mann-Whitney test (****p < 0.0001). Data is represented as mean ± SEM of three
technical replicates
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(Additional file 3: Figures S3i, j). In summary, these data re-
veal that we can detect disease relevant early alterations,
particularly concerning lysosomal function in CLN3Q352X
mutant cerebral organoids, which may precede more severe
phenotypes including cell death.
Whole-transcriptome analysis reveals impaired
development in CLN3Q352X cerebral organoids
Comparative transcriptomic analyses in the context of
CLN3 disease are very limited [32]. Therefore, we used
those CLN3 mutant organoids that were able to develop
Fig. 3 A large fraction of CLN3Q352X hiPSC-derived cerebral organoids exhibit impaired growth. a CLN3Q352X organoids fail to expand and form
neuroectodermal protrusions at three days of differentiation (3DOD) compared to the Control organoids. Scale bar, 200 μm. b Size measurements
of organoids at 3DOD show a decrease in the area of the CLN3Q352X organoids. Area was calculated on ImageJ (NIH) by manually delineating the
perimeter as regions of interest (ROI). Data points represent single organoids from three independent derivations (total n = 20 organoids).
Comparison was performed applying a Mann-Whitney test between the two groups. c A proportion of CLN3Q352X organoids remains
underdeveloped after 55DOD. Small Matrigel-embeded organoids are highlighted with a dashed yellow circle. d Quantification of the percentage
of CLN3Q352X mutant organoids reaching a complete development. Data points represent percentage per organoid derivation (total n = 13
different organoid generations). Comparison between the two groups was performed with an unpaired t-test with Welch’s correction. For B and
D, data is represented as mean ± SEM (p < 0.01**, p < 0.0001****). e Fully developed organoids from both Control and CLN3Q352X mutant
genotypes express forebrain marker FOXG1 (green) and cortical layer identities: SATB2 (red) for later-born superficial-layer identity and CTIP2 and
TBR1 for early-born deep-layer identity (CTIP2 and TBR1, both green), at 55DOD. They also express the neuronal marker MAP 2 (red) and neural
stem cell markers SOX2 (white) and Nestin (green). Scale bars, 200 μm. f. Representative western blots for the some of the markers mentioned
above. Quantifications show similar expression in fully developed CLN3Q352X organoids compared to the Controls at 55DOD. Data points
represent single different organoids (n = 7 different organoids per condition). g Representative TEM pictures of the ultrastructural neuronal
features of both organoid cultures at the same stage. Nerve fibers are highlighted in a yellow dashed boxed and higher magnification picture is
offered at the right side to visualize neurofilaments (nf; <, both in red), which are present in both genotypes, as well as synaptic vesicles (sv; black
dashed circles). Scale bars represent 1 μm, 200 nm for magnified areas
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and performed whole-transcriptome RNA-seq analysis
to detect early disease signatures at the gene expression
level. In order to gain a deeper understanding of JNCL
disease-related dysregulations at a systems-level, we
employed a differential gene regulatory network (GRN)
based analysis to reconstruct phenotype-specific net-
works representing the CLN3Q352X-diseased (mutant)
and Control (healthy) phenotypes [5, 14, 65]. Differential
expression analysis (DEA) resulted in 972 genes to be
significantly (Benjamini Hochberg corrected p-value
≤0.05 and logFC > 1) differentially expressed (up- and
down-regulated) between the Control and the
CLN3Q352X mutant cerebral organoids (Fig. 5a). The
hierarchical clustering analysis revealed the presence of
Fig. 4 JNCL cerebral organoids recapitulate disease hallmarks in the neuronal tissue. a Representative TEM pictures highlighting increased
presence of autophagic vacuoles (AVs, dashed yellow line) in the CLN3Q352X organoids. Scale bars, 1 μm. b Quantification of AV area, measured
on ImageJ by region of interest (ROI) definition, reveals a significant increase in the size of the vacuoles in the CLN3Q352X organoids. Comparison
from 14 Control and 20 CLN3Q352X random AV profiles was done using Mann-Whitney test, *p < 0.05. Data points indicate single AVs measured
per condition. c Representative TEM pictures of fingerprint inclusions (FPPs) detected exclusively in the CLN3Q352X organoids. Scale bar, 500 nm. d
Representative EM pictures of curvilinear bodies (CVB) found exclusively in the CLN3Q352X organoids. Scale bar, 500 nm. e Representative western
blot staining for TPP1 showing a slight increase in the CLN3Q352X organoids. f Quantification of the TPP1 levels from western blots. Data points
represent individual organoids (n = 12 organoids from at least three independent derivations) (Welch’s test; **p < 0.01). g ELISA quantification of
CTSD protein levels. Data points represent single different organoids (n = 8 organoids generated in at least three independent derivations)
(Welch’s test; **p < 0.01). h Astrocytosis shown by increased GFAP positive (green) staining in the CLN3Q352X organoids compared to the controls.
Scale bars, 100 μm. i Image analysis of GFAP and MAP 2 positive staining in organoid sections, normalized by nuclear (Hoechst positive) staining.
Data points represent different organoid sections (n = 8 Control and 9 CLN3Q352X sections taken from different organoids generated in at least
three independent derivations). Comparison evaluated by Kolmogorov-Smirnov test (*p < 0.05; ns, not significant). Data in B, F, G and I is shown
as mean ± SEM
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two clearly distinct groups, with different gene expres-
sion signatures, which correlate with the presence of the
CLN3Q352X mutation (Fig. 5a). The reconstructed
CLN3Q352X-diseased network comprised 353 genes and
641 interactions, whereas the Control healthy network
contained 298 genes and 399 interactions (Add-
itional file 4: Figures S4a, b). Interestingly, gene ontology
(GO) analysis of the CLN3Q352X–diseased network
revealed that most of the up-regulated genes in the net-
work were significantly enriched in cellular processes re-
lated to development, such as tissue development (GO:
0009888, FDR:5.84E-29), multicellular organism devel-
opment (GO:0007275, FDR:6.67E-32) and extracellular
matrix (ECM) organization (GO:0030198, FDR:3.68E-
36). On the other hand, most downregulations were
targeting biological processes related to antigen process-
ing and presentation via the class I major histocompati-
bility complex (MHC I) (GO:0002480), FDR: 9.73E-124)
(Fig. 5b). Interestingly, antigen presenting cell abnormal-
ities have been previously reported in a CLN3-deficient
mouse model [31]. Furthermore, pathway enrichment
analysis highlighted significant dysregulations in molecu-
lar pathways related to stem cells and development
(Fig. 5c). Particularly, the TGF-beta, WNT and BMP sig-
naling pathways were found to be significantly associated
with the disease specific network, these signaling path-
ways are well characterized for their fundamental roles
in embryonic development and homeostasis [72, 80, 82].
This suggested that dysregulations of developmental
pathways and processes in CLN3Q352X cerebral orga-
noids constitute a disease signature, already at early
stages during the brain development. Additionally, we
analyzed the expression levels of genes related to cortical
morphogenesis and found that transcription factors crit-
ical in central nervous system development, such as
FOXG1 [30], FEFZ2 [22], CTIP2 [56], SATB2 [11],
Fig. 5 Whole-transcriptome analysis reveals impaired development in CLN3Q352X cerebral organoids. a Heatmap clustering the differentially
expressed genes between Control (healthy) and CLN3Q352X (mutant) brain organoids. b Gene enrichment analysis of CLN3Q352X network. Genes
that are upregulated in disease phenotype were significantly enriched in cellular processes highlighted in green, while downregulations are
depicted in red. c Pathway enrichment analysis of the CLN3Q352X network. Pathway up-regulations are highlighted in green, while down-
regulations are marked in red. d Log 2 Fold change expression values for genes related to brain development and cortical morphogenesis were
generally decreased in CLN3Q352X. e Log 2 Fold change expression values for genes related to synapses, which were mostly downregulated in
the CLN3Q352X organoids. Genes in D and E are specifically differentially in our dataset (but not necessarily present in the networks) and belong
to the pathways extracted from Pathway unification database (PathCards)
Gomez-Giro et al. Acta Neuropathologica Communications           (2019) 7:222 Page 9 of 19
TBR1 [21] or NEUROD2 [57] were predominantly
downregulated in the CLN3Q352X organoids (Fig. 5d).
Moreover, expression of genes encoding relevant synap-
tic proteins, such as amino acid transporters from the
SLC6 and the SLC17 families, as well as neurotransmit-
ter receptors, such as γ-Aminobutyric acid (GABA) re-
ceptor GABRA2 and dopamine receptor DRD1, were
also decreased (Fig. 5e). These downregulations are indi-
cative of specific alterations in cortical neuronal specifi-
cation and synapse formation in CLN3Q352X organoids.
CLN3Q352X cerebral organoids display early synaptic and
neurotransmitter defects
Previous studies in mouse models reported changes in pre-
synaptic release and region-dependent neural network ac-
tivity dysfunction due to CLN3 deficiency, especially
affecting GABAergic and glutamatergic transmission,
particularly in the amygdala, hippocampus, and cerebellar
networks [13, 28]. Immunofluorescence stainings for synap-
tophysin (presynaptic marker) and postsynaptic density
protein 95 (PSD95; postsynaptic marker) revealed a signifi-
cant decrease in presynaptic and postsynaptic counts in
CLN3Q352X mutant organoids (Fig. 6a, b). These synaptic
marker proteins have been shown to manifest changing
patterns during the human frontal cortex development
[24], but alterations in the levels of these proteins in the
cerebral organoids model complement the gene expression
data (Fig. 5) highlighting impairments in synapse formation.
To gain further insights, we compared the metabolic pro-
files of CLN3Q352X mutant cerebral organoids to the iso-
genic controls. Unsupervised clustering separated both
genotypes, highlighting dysregulations in 66 different me-
tabolites between the two, with most of the metabolites be-
ing less represented in the CLN3Q352X mutant organoids
(Fig. 6c). From these metabolites, a total of 31 were identifi-
able (Additional file 6: Table S3). Within these metabolites,
we detected a significant decrease in some amino acids,
such as tryptophan and lysine and interestingly also in
neurotransmitters, like the γ-aminobutyric acid (GABA).
Creatinine, a putative metabolite biomarker for several neu-
rodegenerative diseases [40], was also significantly down-
regulated in the mutant organoids (Fig. 6d, e, Additional
file 6: Table S4). To further demonstrate the downregula-
tion of the GABA system, the vesicular GABA transporter
vGAT was checked via immunostaining, revealing a signifi-
cant decrease in the evaluated CLN3Q352X mutant organoid
sections (Fig. 6f, g). In summary, these findings reveal an
impairment in synapse formation and neurotransmitter
production in CLN3 mutant cerebral organoids.
Discussion
The impact of CLN3 mutations on neurodevelopment is
clearly understudied and especially studies using human
in vitro models are missing. The advent of iPS cell
technologies allows the development of such models,
which are especially relevant in rare disease studies,
where the paucity of available patient samples limits re-
search development. In this context, the generation of
isogenic cell lines by means of CRISPR/Cas9-mediated
genome editing is of great importance, especially to iso-
late the effect of the disease-causing mutations from the
patient-specific genetic background. Moreover, advances
in three-dimensional organoid cultures foster the use of
the human iPS cells to study neurodevelopment [1, 45].
Here, we generated a CLN3 mutant hiPS cell line by
introducing the c.1054C→T pathologic variant in the
CLN3 gene and used organoid technology to obtain a
neurodevelopmental in vitro model of CLN3 disease,
which recapitulates key disease features and allows to
study the impact of the mutation on brain development.
While characterizing the isogenic cell pair, we discov-
ered that the introduced mutation promotes the exclu-
sion of the constitutive mutated exon from the
transcript. More importantly, we were able to confirm
the existence of the alternative spliced variant in patient
cells carrying the same mutation. This phenomenon was
not previously reported for this mutation and is most
likely occurring in other nonsense CLN3 mutations lo-
cated in exon boundaries, gaining specifically relevance
when designing effective therapeutic strategies. In
addition, the value of the here described isogenic pair
was further demonstrated by showing distinct disease-
specific phenotypes in different in vitro cultures. Firstly,
in this study, hiPSC-derived endothelial cells recapitulate
organellar pathology and present JNCL-type storage ma-
terial. Secondly, hiPSC-derived cerebral organoids also
displayed the disease hallmark, finger print material ac-
cumulation, interestingly found in combination with
curvilinear bodies. Additionally, we show that storage
pathology is co-occurring with alterations in the levels of
lysosomal enzymes, such as TPP1 and CTSD, which
have been described in various pathological conditions
such as neurodegenerative lysosomal storage disorders,
inflammation, cancer and aging [25, 39]. Taken together,
these results validate the here described isogenic pair as
a suitable human model for JNCL, which recapitulates
key features of disease pathology both in two-
dimensional non-neuronal and three-dimensional neural
cell cultures.
Previous studies using cerebral organoids as model for
rare diseases with known genetic risk factors, such as
primary microcephaly [45] or Sandhoff disease [1] re-
ported a markedly reduced or increased organoid size,
respectively, with impaired neuronal differentiation in
patient organoids. We observed that the CLN3 mutant
cells were considerably sensitive to the cerebral organoid
differentiation, failing to form neuroepithelial buds after
the start of differentiation and impairing their complete
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Fig. 6 (See legend on next page.)
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development. It is noteworthy that about half of the
CLN3Q352X organoids across the different organoid gen-
erations presented extremely severe development abnor-
malities, whereas the rest developed normally in terms
of brain and cortical identity. Provided that the starting
population for the organoid generation was a pool of
gene edited hiPS cells, the maturation failure could be
possibly due to different expression levels of the two
mutant variants of the CLN3 gene and dissimilar
amounts of truncated protein. We hypothesize that com-
pensatory mechanisms present within some of the edited
cells may favour their further maturation. Therefore, we
used the fully-developed organoids to unravel less severe
disease signatures, caused by the presence of the
CLN3Q352X mutation, which may be present already dur-
ing brain development and precede end-stage lysosomal
storage defects. Transcriptomic profiling indicated that
pathways involved in cell fate differentiation, prolifera-
tion and tissue and system developmental processes
were altered in the CLN3Q352X organoids compared to
the controls. A closer look into subsets of genes
appointed to specific downregulations affecting pathways
related to corticogenesis and synapses. Although fully-
developed organoids for both genotypes presented simi-
lar levels of cortical proteins, such as FOXG1 and
SATB2, mRNA levels evaluated at the same time-point
revealed downregulations for the corresponding genes in
the CLN3Q352X mutant organoids. We consider that, at
the stage of analysis, the system is already showing alter-
ations at the gene expression level, but is still able to
compensate for these alterations by using the available
transcripts to produce sufficient levels of the corre-
sponding proteins. On the other hand, recent studies re-
ported alterations in the synaptic compartment in CLN3
animal models revealing neurotransmission defects [28]
and molecular regulators of synaptic stability [48].
Changes in proteins involved with synaptic function/sta-
bility were previously reported in mouse models of dif-
ferent NCL forms [37]. In the CLN3 mutant organoids,
evaluation of pre- and post-synaptic proteins revealed a
marked decrease in these proteins, suggesting potential
alterations in synapse formation during brain develop-
ment. To evaluate if synapse defects have an influence
on neurotransmitter levels, we studied the metabolome
of the mutant cerebral organoids, with special focus on
metabolites that are implicated in neurotransmission.
We were able to find imbalances particularly related to
the GABA metabolism, but also in other relevant cere-
bral metabolites. This constitutes an interesting finding,
since GABAergic interneurons are affected in JNCL dis-
ease pathogenesis in various animal models and human
patients [50, 53]. The alterations discovered using the
cerebral organoid model support the concept of a devel-
opmental component to JNCL pathology. We suggest
that dysregulated gene expression in key pathways for
development and synaptic alterations, particularly affect-
ing GABAergic populations might precede the accumu-
lation of pathologic storage material and the impairment
of the lysosomal enzymatic profile, affecting the trajec-
tory of cortical development in children with JNCL.
The advantage of using gene regulatory networks to
link genes based on their interaction at the transcrip-
tional level is that it allows detecting hub genes that
could be candidate genes for modulation to revert the
disease phenotype and bring the mutant network closer
to the healthy one. As a proof of principle, we performed
in silico network perturbations [84] to identify the most
influential genes in the diseased network [36]. Single and
multi-gene perturbations revealed several transcription
factors, listed in Additional file 6: Table S5, that play an
(See figure on previous page.)
Fig. 6 Dysregulations at the synapses might precede other phenotypes in CLN3Q352X cerebral organoids. a Representative confocal images of
synaptic protein staining for Synaptophysin (red) and PSD95 (green). Scale bars, 200 μm. Zoomed regions with TUJ1 (white) neuronal staining. b
Quantification of the Synaptophysin and PSD95 positive particles normalized to nuclear (Hoechst positive) count. Two regions of interest (ROI) per
organoid section were imaged. Following automatic thresholding, the particle analyzer tool from ImageJ (NIH) was used to quantify punctate
stainings -PSD95 and Synaptophysin- and the ITCN nuclear count tool to quantify Hoechst positive nuclei. Each data point represents a region of
interest (ROI). Total n per group equals 10 sections taken from organoids generated in at least three independent derivations. Comparison
between groups was performed with a Mann-Whitney test (**p < 0.01; ns, not significant). c Heatmap representing hierarchical clustering of
deregulated metabolites between the Control and the CLN3Q352X mutant organoids. 5 different pools of 3 organoids were analyzed and 3
technical replicates per measurement were performed. d Table containing cerebral tissue metabolites. Arrows indicate relative increase or
decrease in the CLN3Q352X mutant organoids compared to the controls. Asterisks mark significantly deregulated metabolites in the mutant
organoids, corresponding to p values. e Neurotransmitter GABA is particularly downregulated in the CLN3Q352X mutant organoids. Significant
differences were evaluated with a Mann-Whitney test comparison (**p < 0.01). Data points represent the average of technical replicates per
organoid pool. Data in B and E is shown as mean ± SEM. f Representative confocal images of inhibitory GABAergic neurons pre-synaptic protein
vGAT staining (green) and MAP 2 positive neuronal areas (red). Single vGAT channel is displayed inside a square dashed box for better
visualization. Scale bars, 20 μm. g Quantification of the vGAT positive particles normalized to Hoechst positive nuclei. Several regions of interest
(ROI) per organoid section were imaged. Following automatic thresholding, the particle analyzer tool from ImageJ (NIH) was used to quantify
vGAT punctate staining and the ITCN nuclear count tool was used to quantify Hoechst positive nuclei. Each data point represents a region of
interest (ROI). Total n per group is 4 sections, one per organoid and each belonging to independent derivations. Comparison between groups
was performed with an unpaired t test with Welch’s correction (*p < 0.05)
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important role in maintaining the diseased phenotype
network. Although the predicted genes are not necessar-
ily responsible for disease onset and progression, they
are predicted to be able to revert most of the diseased
gene expression program upon perturbation and thus
would be interesting candidates in future studies that
could lead to a significant reversion of the pathologic
phenotype upon modulation.
The acquisition of an isogenic pair in the context of a
rare disease, such as JNCL, overcomes the primary limi-
tation of access to patient material. Moreover, having
hiPSC lines that can be differentiated into several cell
types allows the study of the pathogeny and the mecha-
nisms of the disease in the different tissues that may be
affected. More importantly, the thorough analysis of a
particular mutation tailors the study in a personalized
manner, and raises the possibility of discovering specific
drugs which can have a direct translational impact in
patients carrying this particular mutation [10]. Addition-
ally, the established three-dimensional cerebral organoid
model for JNCL fosters human in vitro studies of early
developmental consequences of this lysosomal storage
disorder, where subtle abnormalities could be found pre-
ceding terminal cell death and neurodegeneration.
Materials and methods
Human iPSC culture
The characterized Gibco (Cat no. A13777) episomal hu-
man induced pluripotent stem cell line was chosen as
control line to conduct the genome editing. Cells were
normally cultured in Matrigel (Crorning, cat no. 354277)
coated plates using Essential 8 medium (Thermo Fisher,
cat no. A1517001) with 1% Penicillin/Streptomycin
(Invitrogen, cat no. 15140122). Cell splitting procedures
were performed using Accutase (Sigma, cat no. A6964)
and plated in the same culturing media, but containing
ROCK inhibitor Y-27632 (Merck Milipore, cat no.
688000) at 10uM for 24 h after dissociation.
Construction of sgRNA vectors and donor plasmids
Introduction of a disease-causing point mutation into
the healthy background A13777 hiPS cell line was per-
formed as previously described [3, 35]. Briefly, sgRNAs
targeting sequences to exon 13 of the CLN3 gene were
selected in silico using a previously published tool [20].
The selected Cas9 sequences with predicted high activity
were then cloned into the pX330 vector (Addgene, 42,
230) as described in Ran et al., 2013 [67]. Bi-allelic tar-
geting of the CLN3 locus was achieved by assembling,
using Gibson assembly (NEB, cat no. E2611L), the corre-
sponding homology arms into two different donor scaf-
folds, carrying either EGFP (Addgene 100,603) or
dTomato (Addgene 100,604) fluorescent reporters [3,
35]. Both donors contained the desired modification to
achieve a homozygous insertion. The donor vectors were
named A235-CLN3-donor-green-Q352X and A236-
CLN3-donor-red-Q352X. All primers used are indicated
in Additional file 6: Table S1 and sgRNA sequence
resulting in successful editing was corresponding to
CLN3-QtoO-B.
Electroporation of parental cells and selection
Following normal dissociation, hiPSC were electropo-
rated using the 4D-Nucleofector System (Lonza) and the
P3 Primary Cell 4D-Nucleofector® X Kit (Lonza, cat no.
V4XP-3024) following the manufacturer’s instructions
and plated in media containing ROCK inhibitor Y27632
at 10uM for 24 h. Cells were cultured until small to
medium size colonies were formed. Then, media was
supplemented with 0.5 μg/mL puromycin (Sigma) until
reaching enough confluence to perform FACS sorting of
the whole population.
Fluorescence activated cell sorting
Human iPSCs were enzymatically disaggregated and pel-
let was re-suspended in cold 1xPBS with 1% BSA (Carl
Roth, cat no. 8076.3) and passed through a 20 μm pre-
separation filter (Miltenyi, cat no. 130–101–812) to en-
sure having a single cell suspension. Cells were sorted
using FACS ARIA III (BD Bioscience), using an 85 μm
size nozzle and a 2.0 neural density filter. Single cell gat-
ing hierarchies on FSC and SSC width and height were
applied (Additional file 1: Figure S1a) and purity mask
was used. CS&T and drop delay calibrations were en-
sured prior to each sorting round.
Cell transfections with transposase mRNA and
genotyping
Removal of the selection module was performed by trans-
fecting the cells with transposase PiggyBac excision-only
mRNA [47] with the Stemfect RNA transfection kit
(Stemgent, cat no. 00–0069) following manufacturer’s in-
structions and the protocol described in Arias-Fuenzalida
et al., 2017 [3]. Double-negative population was again
purified by FACS sorting of the whole population. Correct
introduction of the mutation was then evaluated via
Sanger sequencing of the flanking genomic region (Fig. 1c),
using primers in Additional file 6: Table S1.
Microarray karyotype
Genomic DNA from the parental (Control) and the edi-
ted (CLN3Q352X mutant) cell lines was isolated using
GenElute Blood genomic DNA Kit (Sigma, cat no.
NA2020). Samples were sent and processed at the Life &
Brain genomics facility from Bonn University, using Illu-
mina iScan technology (Illumina).
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Evaluation of exon skipping in the CLN3Q352X mutant line
Total RNA was isolated using the RNeasy Mini Kit (Qia-
gen, cat no. 74106) following the manufacturer’s instruc-
tions. An on-column DNase digestion step was
performed with RNase-Free DNase Set (Qiagen, cat no.
79254). Complementary DNA was synthesized using
High Capacity RNA-to-cDNA Kit (Invitrogen, cat no.
4387406). Reverse Transcription PCR reaction was per-
formed using GoTaq G2 Hot Start Green Master Mix
(Promega, cat no. M7423) using the primers listed in
Additional file 6: Table S1.
Derivation and culture of endothelial cells
Endothelial cells were differentiated from hiPS cells fol-
lowing a modified version of Prasain et al., 2014 protocol
[64]. A density of 250.000 hiPS cells were seeded per
well of a Matrigel-coated 6-well plate and cultured on
Essential 8 with 1% Penicillin/Streptomycin plus 10uM
ROCK inhibitor for 24 h (day minus three). Media was
exchanged at day minus two for MEF conditioned media
(R&D Systems, cat no. AR005) supplemented with 10
ng/mL bFGF (PreproTech, cat no. 100-18B). At day
minus one, media was refreshed completely with the
same media and the addition of 4X Matrigel. Media was
changed at day zero to RPMI media (Thermo, cat no.
21875–034) with the addition of 1X B27 without vitamin
A (Life Technologies, cat no. 12587–10) and 10 ng/mL
Activin A (Life Technologies, cat no. PHC9564) to direct
cells toward mesodermal lineage. From day one on-
wards, cells were cultured in RPMI with B27 media, with
the addition of 10 ng/mL bFGF, 10 ng/mL BMP4 (Pre-
proTech, cat no. 120–05) and 10 ng/mL VEGF165 (Pre-
proTech, cat no. 100–20). Cells were sustained in
differentiation media conditions for two additional
weeks.
Generation and culture of human cerebral organoids
Human whole brain organoids were derived from the
isogenic pair hiPSCs following the Lancaster and Kno-
blich, 2014 protocol [44]. Cerebral organoids were main-
tained under differentiation conditions for 55 days after
the embedding day (total 66 days).
Electron microscopy
Cultured cells and organoids were fixed using a modified
Karnovsky’s fixative (pH 7.4), containing 2% PFA and 2%
glutaraldehyde in 0.1 M sodium cacodylate buffer for 3 h
at RT on a shaker. After this time, fixative was replaced
with fresh solution and organoids were incubated for 2
days at 4 °C on a shaker. Organoids were then rinsed
several times with 0.1M cacodylate buffer. Cultured cells
were partially scraped and concentrated in a pellet then
re-suspended in 2% low melting point agarose, the other
part of the monolayer was flat embedded. All samples
were post-fixed in 1% osmiumtetroxide, 1.5% potassium-
ferrocyanide in 0.1 M cacodylate buffer and stepwise
dehydrated in ethanol, including in-bloc 0.5% uranyl
acetate staining during 70% ethanol incubation. Samples
were embedded in epon and sectioned ultrathin at 70
nm. Sections were collected on copper grids and stained
with lead. Samples were analyzed on a Tecnai 12 elec-
tron microscope (Thermofisher Scientific, Eindhoven,
The Netherlands) and representative areas were docu-
mented with a 2 K CCD-camera (Veleta, EMSIS, Mün-
ster, Germany). Three different blocks of each condition
were sectioned and examined. Cultured endothelial cells
were analysed as scraped cell sample, thus randomly ori-
entated. Flat embedded cells were investigated in a polar
manner from basolateral to apical side. Organoid sam-
ples were sectioned in three different orientations:
peripheral, cross-sectioned through the centre and sec-
tioned from the centre part of the organoids. Represen-
tative pictures are shown in the corresponding figures in
the results section.
Immunofluorescence in cells
Cell fixation was done using 4% PFA in PBS for 15 min
at RT. Cells were washed then 3x with PBS for 5 min at
RT and permeabilized using 0.05% Triton-X100 in PBS
for 10 min at 4 °C. Blocking was performed for 1 h at RT
with 10%FCS in PBS. Incubation with the corresponding
primary antibodies at the required concentrations was
done overnight at 4 °C in blocking buffer. For pluripo-
tency stainings, SSEA4 (Abcam, cat no. ab16287, 1:50),
Oct4 (Abcam, cat no. ab19857, 1:400), TRA-1-60 (Milli-
pore, cat no. MAB4360, 1:50), TRA-1-81 (Millipore, cat
no. MAB4381, 1:50), Nanog (Millipore, cat no. AB5731,
1:200) and hSox2 (R&D Systems, cat no. AF2018, 1:100)
were used. Endothelial cells were characterized by the
expression of CD31 (Dako, cat no. M082301, 1:100) and
stained for SCMAS (Abcam, cat no. ab181243, 1:100),
LAMP1 (Abcam, cat no. ab25630, 1:100), GM130 (BD
Bioscience, cat no. 610822, 1:200) and Rab7 (Abcam, cat
no. ab50533, 1:200) for subcellular studies. Incubation
with secondary antibodies was done after 5 min 3x wash-
ing steps with PBS, for 2 h at RT in blocking buffer. All
secondary antibodies (Invitrogen) were conjugated to
Alexa Fluor fluorochromes and used in a 1:1000 dilution
together with a nuclei counterstain by Hoechst 33342
(Life Technologies, cat no. H21492). Cells were washed
3x with PBS, and either mounted with Fluoromount-G
mounting medium (Southern Biotech, cat no. 0100–01)
or covered with PBS and imaged directly after.
Immunofluorescence in organoid sections
Organoids were fixed with 4% PFA overnight on a
shaker at 4 °C and washed 3x with PBS. Afterwards, they
were embedded in 3% low-melting point agarose
Gomez-Giro et al. Acta Neuropathologica Communications           (2019) 7:222 Page 14 of 19
(Biozym, cat no. 840100) in PBS and incubated at RT
until the agarose solidified. The agarose block was either
covered with PBS and kept at 4 °C or sectioned immedi-
ately. If not indicated otherwise, 80 μm sections were cut
using a vibratome (Leica VT1000s), set to a speed of 6.1
and a frequency of 9. Sections were permeabilized and
blocked in one-step with PBS containing 0.1% sodium
azide, 0.1% sodium citrate, 5% goat or donkey serum
and 2% BSA, for 90 min at RT on a shaker. Incubation
with the corresponding primary antibodies at the re-
quired concentration was performed in blocking buffer
containing 0.1% Triton-X for 48 h at 4 °C. Synaptophysin
(Abcam, cat no. ab8049, 1:50), PSD95 (Invitrogen, cat
no. 51–6900, 1:300), vGAT (Sigma, cat no. HPA058859,
1:200), TUJ1 (Millipore, Cat no. AB9354) and MAP 2
(Abcam, cat no. ab32454, 1:100) antibodies were used to
evaluate synaptic markers. GFAP (Millipore, cat.no.
AB5541, 1:1000) and MAP 2 (Abcam, cat no. ab32454,
1:100) antibodies were used for astrocytosis assessment.
CTIP2 (Abcam, cat no. ab18465, 1:100), SATB2 (Abcam,
cat no. 34735, 1:100), TBR1 (Abcam, cat no. 31940, 1:
300) and FOXG1 (Abcam, cat no. 18259, 1:1000) anti-
bodies were used for brain organoid characterization.
SOX2 (Abcam, cat no. ab97959, 1:200) and Nestin (BD
Bioscience, cat no. 611659, 1:600) primary antibodies
were used for neural stem cell evaluation. After 3x wash
with PBS for 15 min at RT, secondary antibodies were
added in a solution of PBS with 0.05% Tween-20. All
secondary antibodies (Invitrogen) were conjugated to
Alexa Fluor fluorochromes and used in a 1:1000 dilution
together with a nuclei counterstain by Hoechst 33342
(Life Technologies, cat no. H21492). Incubation was
done for 2 h at RT on a shaker and protected from light.
Sections were washed 3x with 0.05% Tween-20 in PBS
for 5 min at RT and 1x with water and then mounted
with Fluoromount-G mounting medium (Southern Bio-
tech, cat no. 0100–01) on a glass slide. Sections were
dried overnight at RT and in the dark.
Western blotting
Cerebral organoids were individually lysed in a Urea con-
taining lysis buffer (7M Urea, 2M Thiourea, 2% CHAPS
and 1M DTT) containing 1X protease inhibitor cocktail
(Sigma). Protein samples were resolved by denaturing SDS
polyacrylamide gel electrophoresis (SDS-PAGE) in 15%
polyacrylamide gels. Proteins were transferred from the gel
to PVDF membranes in an iBlot2 device (Thermo). Mem-
branes were incubated with SuperSignal West Pico Chemi-
luminescent Substrate (Thermo, cat no. #34580). Enhanced
chemiluminiscent signal was detected in a STELLA im-
aging system. Evaluated antibodies were TPP1 (Abcam, cat
no. ab96690, 1:1000), SCMAS (Abcam, cat no. ab181243, 1:
1000), RIP1 (BD Bioscience, cat no. 610459, 1:1000), RIP3
(Abcam, cat no. ab152130, 1:1000), FOXG1 (Abcam, cat
no. 18259, 1:500), SATB2 (Abcam, cat no. 34735, 1:250)
and GAPDH (Abcam, cat no. 9485, 1:1000).
Human Cathepsin D ELISA detection
Cathepsin D levels were evaluated using the Human Ca-
thepsin D SimpleStep ELISA kit (Abcam, cat no.
ab213470) following the manufacturer’s instructions.
Briefly, cerebral organoids were individually disrupted in
200 μL of chilled 1X PTR cell extraction buffer and incu-
bated for 20 min on ice, while homogenizing with either
a pipette tip or needles. Samples and standards were
loaded into the 96-well assay plate strips and incubated
for 1 h at RT together with the antibody cocktail. Wells
were washed 3x in 1x PT wash buffer and incubated
with TMB substrate for 10 min. Reaction was the
stopped and optical density at 405 nm measured in a
Cytation 5 plate reader (BioTek) as an endpoint meas-
urement. For normalization, sample protein concentra-
tion was quantified using Protein Quantification Assay
(Macherey-Nagel, cat no. 740967.250).
Terminal deoxynucleotidyl transferase biotin–dUTP nick
end labeling (TUNEL) assay
General apoptosis within the organoids was detected
using the In situ cell death detection kit, TMR red
(Merck, cat no. 12156792910) following the manufac-
turer’s instructions, adapted to screen organoid sections.
Briefly, organoid sections were permeabilized with 0.1%
Triton-X in 0.1% sodium citrate for 8 min at 4 °C. After
3x wash with PBS, sections were incubated with the
TUNEL reaction mixture for 1 h at 37 °C and in a hu-
midified atmosphere and in the dark. Hoechst 33342
(Life Technologies, cat no. H21492, 1:1000) was added
to the mix to visualize the nuclei. Positive controls were
treated in a previous step with 5uL of Deoxyribonuclease
I (DNase I) (Sigma-Aldrich, cat no. AMPD1-1KT, 1unit/
uL) for 10 min at RT to induce DNA strand breaks.
Negative controls were incubated with label solution
only. Following 3x wash with PBS, sections were
mounted with Fluoromount-G mounting medium
(Southern Biotech, cat no. 0100–01) on a glass slide.
Sections were dried overnight at RT and in the dark. Im-
aging was performed in Operetta High-content Imaging
System (Perkin Elmer) in a range of 520-560 nm excita-
tion and 570-620 nm emission.
RNA-Seq
Total RNA was isolated from cerebral organoids using
the RNeasy Mini Kit (Qiagen, cat no. 74106). Six repli-
cates per condition, constituted by a pool of three orga-
noids per replicate, were extracted. RNA quality was
assessed in a Bioanalyzer 2100 (Agilent). In a second
step, library preparation for sequencing was done with
1 μg of total RNA using the TruSeq mRNA Stranded
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Library Prep Kit (Illumina) according to manufacturer’s
protocol. Pooled libraries were sequenced on Next-
Seq500 using manufacturer’s instructions.
RNA-Seq data processing and analysis
Illumina Hi-Seq single-end reads were filtered by using
BBDuk (trimq = 10 qtrim = r ktrim = r k = 23 mink = 11
hdist = 1 tpetbominlen = 40; http://jgi.doe.gov/data-and-
tools/bb-tools/) to remove illumina adapters, PhiX li-
brary adapters, and to quality trim the reads. FastQC [2]
was used to check the quality of the reads in order to as-
sure that only high-quality reads are retained for subse-
quent analysis. Resulting reads were mapped to human
GRCh37 genome by using tophat (version 2.1.1) [75] (li-
brary-type = fr-secondstrand) and Bowtie2 (version
2.3.2.0). Obtained alignment files were sorted by using
samtools (version 1.6–5) [46] and the statistics of the
alignment rate were obtained by using samtoolsflagstat.
Cufflinks (version 2.2.1) [75] was used to quantify the
transcripts and resulting expression values per gene were
obtained in FPKM (fragments per kb per million reads).
Differential expression analysis between the Control and
CLN3Q352X mutant samples was conducted by using the
cuffdiff program from the cufflinks tool. Only signifi-
cantly, differentially expressed genes with an absolute
log2 fold change greater than 1 were considered for sub-
sequent analysis.
Gene regulatory network reconstruction
For the set of significantly differentially expressed genes
(DEGs), the experimentally validated direct gene-gene
interactions were retrieved from MetaCore (Clarivate
Analytics). The interaction types belonging to categories
“Transcription regulation” and “Binding” were kept in
the prior knowledge network (PKN) from MetaCore.
Differential network inference method proposed by [84]
was used to prune the network edges (interactions)
which are not compatible with the discretized gene ex-
pression program of the respective phenotype. Briefly,
this method uses discretized differential gene expression
data and infers two networks representing the mutant
(disease) and cotnrol (healthy) phenotypes as steady
states. Some of the interactions derived from MetaCore
have an unspecified regulatory effect, as the exact mech-
anism of regulation is not known in those cases. The
proposed algorithm also infers the regulatory effect (acti-
vation or inhibition) for such unspecified interactions
based on the given gene expression pattern.
Identification of network perturbation candidates
The differential network topology allowed us to iden-
tify common and phenotype-specific positive and
negative elementary circuits, i.e. a network path which
starts and ends at the same node with all the
intermediate nodes being traversed only once. These
circuits have been shown to play a significant role in
maintaining network stability [27] and the existence
of these circuits is considered to be a necessary con-
dition for having a stable steady (network) state [74].
Considering the importance of these circuits, it has
been shown that perturbation of genes in the positive
circuits induces a phenotypic transition [19]. Further-
more, the differential network topology also aids in
identifying the differential regulators of the genes,
which are common to both phenotype-specific net-
works. Altogether, the differential regulators and
genes in the elementary circuits constitute an optimal
set of candidate genes for network perturbation as
they are able to revert most of the gene expression
program upon perturbation. Identification of network
perturbation candidates was carried out by using the
Java implementation proposed by Zickenrott and col-
leagues [84].
In silico network simulation analysis for phenotype
reversion
The Java implementation from Zickenrott and colleagues
[84] was used to perform the network simulation ana-
lysis by perturbing multi-target combinations of up to
four candidate genes identified in the previous step. The
used algorithm gives a ranked list of single- and multi-
gene(s) combinations (4 genes maximally) and their
scores, which represent the number of genes whose
expression is being reverted upon inducing the chosen
perturbation in the diseased network. If a single- or
multi-gene(s) perturbation combination obtains a high
score, it is indicative of its ability to regulate the expres-
sion of a large number of downstream genes, hence play-
ing a crucial role in the maintenance and stability of the
phenotype under consideration.
Gene and pathway enrichment analyses
MetaCore (Clarivate Analytics) and EnrichNet [23] were
used to conduct the gene ontology (GO) and pathway
enrichment analysis. The set of upregulated genes in the
diseased network were used to identify the most over-
represented biological processes and molecular functions
associated with the genes in the network. Similarly, the
most enriched biological pathways associated with genes
that are upregulated in the pathologic network pheno-
type were described. The same kind of analysis was con-
ducted to show downregulations in biological processes
and pathways.
Metabolomics
Metabolites from cerebral organoids were extracted and sub-
sequently prepared for non-targeted gas chromatography-
mass spectrometry (GC-MS) measurements, as previously
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described [34]. Five replicates per condition, constituted by a
pool of three organoids per replicate, were extracted. Orga-
noids were homogenized using a bead mill homogenizer sys-
tem (Precellys24) and ceramic beads to produce a
homogeneous suspension. Metabolites were then ex-
tracted with water/methanol/chloroform, yielding a
three-phase system, where polar metabolites are
enriched in the upper phase, non-polar metabolites in
the lower phase and cell debris form a solid inter-
phase. Polar phase was transferred into a sample vial
and solvents were evaporated in a rotary vacuum
evaporator at − 4 °C until dry and stored at − 80 °C
until GC-MS analysis. Subsequent metabolic profiling
is performed with gas chromatography coupled to
mass spectrometry on an Agilent 7890B GC - Agilent
5977A MSD system. Post processing of the data was
performed with the MetaboliteDetector software
(http://md.tu-bs.de). Data was then manually curated,
removing any possible contamination of external com-
pounds due to sample preparation and the internal
standards.
Image acquisition
Brightfield and fluorescence representative images of
the gene editing procedure, cell culture characteriza-
tion and organoid images for area measurements
were acquired using an inverted microscope (Zeiss
Axio ObserverZ1). Synapse and autofluorescence ana-
lyses were performed on organoid sections imaged on
a confocal (Zeiss LSM 710) laser-scanning micro-
scope. Sections were usually imaged at 20-x and ei-
ther tile scanning of the whole organoid sections
were acquired or random regions of interest (ROI)
within the sections were selected. Images were fur-
ther processed with Zen Software (Zeiss) and quanti-
fications were performed on ImageJ (NIH). The high
content microscope OPERA QEHS spinning disk
microscope (Perkin Elmer) was used for 2D endothe-
lial cell imaging, using a 63-x water immersion ob-
jective. On the other hand, Operetta High-content
Imaging System (Perkin Elmer) was used to acquire
volumetric images (Z-stacking) of the entire organoid
sections (Tile-scanning). The 20-x objective was used
for this purpose. In both cases, volumetric images of
plated cells and 3D images of cerebral organoids –
e.g. TUNEL assay- were analyzed in Matlab (Version
2017b, The MathWorks Inc.), with in-house devel-
oped image analysis algorithms which automate the
segmentation of nuclei and allow structure-specific
feature extraction. The expression level of any
marker was expressed as positive pixel of the marker,
and commonly normalized by the pixel count of
Hoechst.
Statistical analysis and graphical representation
All the statistical analysis were performed in GraphPad
Prism (Version 6.01). Significance asterisks represent
P < 0.05 *, P < 0.01 **, P < 0.001 ***, P < 0.0001 ****; ns
stands for not significant.
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